Advanced Search
YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
Citation: YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116

Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China

More Information
  • In order to provide enlightening experience for the establishment of reasonable and diversified orphan drugs into the reimbursement system in China, the official websites of the National Institute for Health and Care Excellence(NICE)and the National Health Service(NHS)in the UK were inspected, collecting and summarizing the relevant documents, on the inclusion of orphan drugs into the reimbursement system. Relevant literatures were analyzed with theoretical studies on the accessibility of medicines for patients with rare diseases. In the NHS system, the inclusion of orphan drugs into the reimbursement system in the UK can be achieved mainly through seven routes, with three routes that are evaluated by NICE(MTA, STA and HST)and four are directly managed by the NHS(specialized commissioning, CDF, IFRs, CtE). Through the analysis of the inclusion of orphan drugs into the reimbursement system and the various problems in the UK, we have found some enlightening experience for the establishment of the reimbursement system for orphan drugs in China.
  • [1]
    Gong SW.Study of management strategies of improving access to orphan drugs in china(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [2]
    Sui BY,Qi XR.Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J].Chin J Health Policy(中国卫生政策研究),2015,8(7):74-78.
    [3]
    National Institute for Health and Care Excellence.Guide to the processes of technology appraisal2014[R].London:NICE,2014.
    [4]
    National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-03-19] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice technology-appraisal-guidance/summary-of-decisions.
    [5]
    National Institute for Health and Care Excellence.Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease[R].London:NICE,2017.
    [6]
    National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-05-17] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions.
    [7]
    National Institute for Health and Care Excellence.Guide to the processes of technology appraisal 2014[R].London:NICE,2014.
    [8]
    National Institute for Health and Care Excellence.Eltrombopag for treating chronic immune(idiopathic)thrombocytopenic purpura[R].London:NICE,2013.
    [9]
    National Institute for Health and Care Excellence.Interim process and methods of the highly specialized technologies programme[R].London:NICE,2017.
    [10]
    National Health Service.Specialized services[EB/OL].[2018-05-18] .https://www.england.nhs.uk/commissioning/spec-services/.
    [11]
    NHS England.Implementation plan for the uk strategy for rare diseases[R].England:NHS England,2018.
    [12]
    NHS England Cancer Drugs Fund Team.Appraisal and funding of cancer drugs from July 2016(including the new Cancer Drugs Fund)- A new deal for patients,taxpayers and industry[R].England:NHS England,2016.
    [13]
    NHS England Cancer Drugs Fund Team.National cancer drugs fund list[R].England:NHS England,2016.
    [14]
    National Institute for Health and Care Excellence.Consultation comments on the draft remit and draft scope for the technology appraisal of cabozantinib for previously treated advanced renal cell carcinoma[R].England:NICE.
    [15]
    Specialized Commissioning Team.Standard operating procedures:individual funding requests[R].England:NHS England,2017.
    [16]
    NHS England.Methods:Commissioning through Evaluation[R].England:NHS England,2017.
    [17]
    National Health Service.Commissioning through evaluation[EB/OL].[2018-05-20] .https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/.
  • Related Articles

    [1]LU Yan, CONG Feng, QIAN Shuai, WEI Yuanfeng, ZHANG Jianjun, LIN Yining, GAO Yuan. Enhanced dissolution and eliminated gelation of lenvatinib mesylate by coamorphous system[J]. Journal of China Pharmaceutical University, 2021, 52(1): 44-51. DOI: 10.11665/j.issn.1000-5048.20210106
    [2]CHEN Ye, DING Jinxi, LIU Ting, TANG Di, WU Fang, WU Liping, DUAN Wanting, XU Yangyan. Status, problems and improvement measures of health insurance reimbursement of national negotiated drugs used in outpatients[J]. Journal of China Pharmaceutical University, 2020, 51(5): 628-634. DOI: 10.11665/j.issn.1000-5048.20200516
    [3]BI Lei, GAO Jing, JIANG Yucui, CHEN Yingna, CHEN Weiping. Effect of Ginseng, Ginseng polysaccharides and Ginsenoside on the human lung cancer cells A549 in co-culture system of TAMs with A549 cells[J]. Journal of China Pharmaceutical University, 2016, 47(6): 744-748. DOI: 10.11665/j.issn.1000-5048.20160619
    [4]DING Jinxi, LIU Yangyang, YAN Jianzhou. Negative effects of drug data protection system on drug availability — an empirical analysis of America lamotrigine case[J]. Journal of China Pharmaceutical University, 2015, 46(4): 493-498. DOI: 10.11665/j.issn.1000-5048.20150418
    [5]DING Zhichen, WEI Guan, DING Jinxi. Orphan drug regime in Japan and enlightenment on China:based on evaluation of orphan drug access in Japan[J]. Journal of China Pharmaceutical University, 2014, 45(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20140122
    [6]DING Jinxi, LIU Weijing, LI Wei, LIU Yangyang, BAI Gengliang. Analysis of orphan drug accessibility and marketing authorization system in China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 111-117. DOI: 10.11665/j.issn.1000-5048.20140121
    [7]DUAN Jin-ao. Establishment of research technological system of resources chemistry of Chinese medicinal materials and its application[J]. Journal of China Pharmaceutical University, 2012, 43(4): 289-292.
    [8]Ratio of alliin/alliinase in catalytic system of garlic[J]. Journal of China Pharmaceutical University, 2010, 41(3): 231-234.
    [9]Research on System of Triptolide-Loaded Poly (D,L-lactic acid) Nanoparticles[J]. Journal of China Pharmaceutical University, 2004, (2): 20-24.
    [10]Effect of Calmodulin Antagonists on the Levels of Hydroxyl Radicals in a Non-Enzyme System[J]. Journal of China Pharmaceutical University, 1993, (6): 351-354.

Catalog

    Article views (855) PDF downloads (1564) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return